Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

139.07USD
15 Feb 2019
Change (% chg)

$0.40 (+0.29%)
Prev Close
$138.67
Open
$140.03
Day's High
$140.03
Day's Low
$138.33
Volume
574,473
Avg. Vol
688,164
52-wk High
$197.00
52-wk Low
$125.84

Latest Key Developments (Source: Significant Developments)

Ironwood Pharmaceuticals Provides Fourth Quarter And Full Year 2018 Investor Update
Wednesday, 13 Feb 2019 

Feb 13 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS PROVIDES FOURTH QUARTER AND FULL YEAR 2018 INVESTOR UPDATE.IRONWOOD PHARMACEUTICALS INC - COMMENCED A REDUCTION IN WORKFORCE BY 35 EMPLOYEES, PRIMARILY BASED IN HOME OFFICE.IRONWOOD PHARMACEUTICALS INC - IRONWOOD'S FIELD-BASED SALES FORCE AND EMPLOYEES EXPECTED TO GO TO CYCLERION ARE EXCLUDED FROM WORKFORCE REDUCTION.IRONWOOD PHARMACEUTICALS INC - WILL INCUR AGGREGATE CHARGES IN Q1 OF 2019 OF ABOUT $3 MILLION TO $4 MILLION RELATED TO REDUCTION IN ITS WORKFORCE.IRONWOOD PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.10.IRONWOOD PHARMACEUTICALS INC - QTRLY TOTAL REVENUE $130.7 MILLION VERSUS $94.2 MILLION.IRONWOOD PHARMACEUTICALS INC - SEES 2019 TOTAL REVENUE TO BE IN RANGE OF $370 MILLION TO $390 MILLION.IRONWOOD PHARMACEUTICALS INC - SEES 2019 SEPARATION EXPENSES, INCLUDED WITHIN SG&A EXPENSES, TO BE IN RANGE OF $30 TO $40 MILLION.IRONWOOD PHARMACEUTICALS - PROGRESSED SEPARATION OF IRONWOOD & CYCLERION INTO TWO PUBLICLY-TRADED COMPANIES WITH COMPLETION EXPECTED FIRST HALF 2019.IRONWOOD PHARMACEUTICALS- U.S. LINZESS. U.S. NET SALES, AS REPORTED BY CO'S U.S. COLLABORATION PARTNER ALLERGAN PLC, WERE $205.2 MILLION IN Q418, UP 5%.IRONWOOD PHARMACEUTICALS INC - EXPECTS TO PROVIDE GUIDANCE ON 2019 NON-GAAP PROFITABILITY FROM CONTINUING OPERATIONS FOLLOWING COMPLETION OF SEPARATION.IRONWOOD PHARMACEUTICALS INC - DOES NOT INTEND TO GUIDE TO PROFITABILITY FROM CONTINUING OPERATIONS ON A GAAP BASIS IN 2019.  Full Article

Appaloosa Sends Letter To Allergan Board Urging Separation Of Chairman, CEO Roles
Tuesday, 5 Feb 2019 

Feb 5 (Reuters) - Appaloosa::APPALOOSA SENDS LETTER TO ALLERGAN BOARD OF DIRECTORS URGING SEPARATION OF CHAIRMAN AND CEO ROLES.APPALOOSA SAYS URGING ALLERGAN BOARD TO SEPARATE ROLES OF CHAIRMAN AND CEO AND TAKE "MEANINGFUL STEPS TO ADDRESS ALLERGAN'S CHRONIC UNDERPERFORMANCE".  Full Article

Allergan Reports Q4 Gaap Loss Per Share Of $12.83
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Allergan plc ::ALLERGAN REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS.Q4 GAAP LOSS PER SHARE $12.83.Q4 EARNINGS PER SHARE ESTIMATE $4.15 -- REFINITIV IBES DATA.AUTHORIZES NEW $2.0 BILLION SHARE REPURCHASE PROGRAM.PROVIDES FULL-YEAR AND Q1 2019 GUIDANCE.ALLERGAN - FOR U.S. SPECIALIZED THERAPEUTICS, RESTASIS NET REVENUE IN Q4 WERE $325.0 MILLION, DOWN 18.8 PERCENT.Q4 2018 GAAP NET REVENUES OF $4.1 BILLION.Q4 REVENUE VIEW $4.01 BILLION -- REFINITIV IBES DATA.QTRLY NON-GAAP PERFORMANCE NET INCOME PER SHARE OF $4.29.REAFFIRMED ITS COMMITMENT TO ACHIEVING A NET DEBT TO ADJUSTED EBITDA RATIO OF LESS THAN 2.5X BY END OF 2020.SEES Q1 GAAP TOTAL NET REVENUES $3.400 - $3.550 BILLION.ALLERGAN - EXPECTS TO DEPLOY NEW SHARE REPURCHASE PROGRAM OVER NEXT 12 MONTHS.ALLERGAN - Q4 NON-GAAP OPERATING INCOME IMPACTED BY LOWER OPERATING MARGIN, REVENUES DUE TO DIVESTITURES, PRODUCTS THAT LOST EXCLUSIVITY, DECLINE IN RESTASIS.SEES Q1 NON-GAAP NET INCOME PER SHARE $3.40 - $3.60.SEES Q1 GAAP NET LOSS PER SHARE $0.39 - $0.20.ALLERGAN - SEES 2019 TOTAL GAAP NET REVENUES $15.000 BILLION - $15.300 BILLION.ALLERGAN - SEES 2019 GAAP EARNINGS PER SHARE GREATER THAN OR EQUAL TO $1.14.FY2019 EARNINGS PER SHARE VIEW $16.32, REVENUE VIEW $15.40 BILLION -- REFINITIV IBES DATA.ALLERGAN - SEES 2019 NON-GAAP EARNINGS PER SHARE GREATER THAN OR EQUAL TO $16.36.Q1 EARNINGS PER SHARE VIEW $3.73, REVENUE VIEW $3.64 BILLION -- REFINITIV IBES DATA.  Full Article

Allergan Winding Down Sales Process For Women's Health Unit - Conf. Call
Monday, 28 Jan 2019 

Jan 29 (Reuters) - Allergan plc ::ALLERGAN PLC CEO SAYS WINDING DOWN THE ADVISORY LED PROCESS FOR WOMEN'S HEALTH BUSINESS - CONF. CALL.ALLERGAN PLC CEO SAYS ANTI-INFECTIVES BUSINESS MORE LIKELY THAN NOT TO BE SOLD - CONF. CALL.ALLERGAN PLC CEO SAYS HIGHEST VALUE PROPOSITION FOR WOMEN'S HEALTH BUSINESS AT THIS TIME IS TO CONTINUE MANAGING IT.ALLERGAN PLC CEO SAYS SALE OF ANTI-INFECTIVES BUSINESS PROBABLE OVER THE NEAR-TERM.  Full Article

Allergan Announces Quarterly Cash Dividend Of $0.74per Share
Friday, 25 Jan 2019 

Jan 25 (Reuters) - Allergan plc ::ALLERGAN ANNOUNCES INCREASED QUARTERLY DIVIDEND AND ANNUAL GENERAL MEETING OF SHAREHOLDERS DATE.ALLERGAN ANNOUNCES INCREASED QUARTERLY DIVIDEND AND ANNUAL GENERAL MEETING OF SHAREHOLDERS DATE.SETS QUARTERLY CASH DIVIDEND OF $0.74PER SHARE.SETS QUARTERLY CASH DIVIDEND OF $0.74PER SHARE.  Full Article

Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of Abp 798, Biosimilar Candidate To Rituximab
Thursday, 24 Jan 2019 

Jan 24 (Reuters) - Allergan plc ::AMGEN AND ALLERGAN ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 1/ PHASE 3 STUDY OF ABP 798, BIOSIMILAR CANDIDATE TO RITUXIMAB.AMGEN INC - STUDY EVALUATED PHARMACOKINETICS, EFFICACY AND SAFETY OF ABP 798 COMPARED TO RITUXIMAB IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS.AMGEN INC - RESULTS DEMONSTRATE THAT STUDY MET ITS PRIMARY ENDPOINT OF PHARMACOKINETIC (PK) SIMILARITY.AMGEN INC - ADDITIONALLY, EQUIVALENT EFFICACY WAS ESTABLISHED AND A SIMILAR SAFETY PROFILE WAS DEMONSTRATED.  Full Article

Allergan Announces Positive 3-Month Topline Results From Second Phase 3 Study Of Bimatoprost SR Implant
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Allergan plc ::ALLERGAN ANNOUNCES POSITIVE 3-MONTH TOPLINE RESULTS FROM SECOND PHASE 3 STUDY OF BIMATOPROST SR (SUSTAINED-RELEASE) IMPLANT FOR LOWERING INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION.ALLERGAN PLC - INITIAL DATA SHOW POTENTIAL FOR VAST MAJORITY OF PATIENTS TO REMAIN TREATMENT FREE FOR AT LEAST 1 YEAR.ALLERGAN PLC - ALLERGAN PLANS US NDA SUBMISSION BIMATOPROST SR (SUSTAINED-RELEASE) IMPLANT IN SECOND HALF OF 2019.ALLERGAN PLC - ALLERGAN IS ALSO CONDUCTING BIMATOPROST SR CLINICAL TRIALS FOR REGISTRATION OUTSIDE UNITED STATES WHICH ARE ONGOING..ALLERGAN - OVERALL, BIMATOPROST SR WAS WELL TOLERATED IN MAJORITY OF PATIENTS.  Full Article

Allergan To Establish Research And Development Presence In Cambridge, Massachusetts
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Allergan plc ::ALLERGAN TO ESTABLISH RESEARCH AND DEVELOPMENT PRESENCE IN CAMBRIDGE, MASSACHUSETTS.ALLERGAN PLC - FACILITY, LOCATED IN KENDALL SQUARE, IS EXPECTED TO OPEN IN 1Q2019.  Full Article

Allergan Suspends Sales Of Textured Breast Implants In European Markets
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - Allergan plc ::ALLERGAN SUSPENDS SALES AND WITHDRAWS SUPPLY OF TEXTURED BREAST IMPLANTS IN EUROPEAN MARKETS.ALLERGAN PLC - WITHDRAWAL DECISION FOLLOWS A COMPULSORY RECALL REQUEST FROM AGENCE NATIONALE DE SÉCURITÉ DU MÉDICAMENT.ALLERGAN PLC - WILL CONTINUE TO WORK THROUGH CE MARK RENEWAL WITH GMED.ALLERGAN PLC - SUSPENSION OF SALES STEMS FROM EXPIRATION OF COMPANY'S CE MARK FOR THESE PRODUCTS.ALLERGAN PLC - ALTHOUGH ALLERGAN DISAGREES WITH ANSM'S REQUEST, COMPANY IS FULLY COOPERATING WITH AUTHORITY.ALLERGAN PLC - "ALLERGAN STANDS BEHIND THE BENEFIT/RISK PROFILE OF OUR BREAST IMPLANT PRODUCTS".ALLERGAN PLC - ANSM HAS NOT IDENTIFIED ANY IMMEDIATE RISK TO HEALTH OF WOMEN WITH TEXTURED BREAST IMPLANTS.ALLERGAN PLC - PLANNING AN APPEAL TO ENSURE APPROPRIATE PATIENTS HAVE ACCESS TO PRODUCTS THAT THEIR SURGEONS RECOMMEND.ALLERGAN PLC - SMOOTH IMPLANTS ARE NOT AFFECTED AND CONTINUE TO BE AVAILABLE FOR PATIENTS.ALLERGAN PLC - UNITED STATES DOES NOT REQUIRE CE MARK SO IT IS UNAFFECTED BY ACTION.ALLERGAN PLC - ANSM REQUEST, AND ACTION TO SUSPEND SALES, IS "NOT BASED ON ANY NEW SCIENTIFIC EVIDENCE REGARDING THESE PRODUCTS".ALLERGAN - ANSM REQUEST, AND SUSPENSION OF SALES OF TEXTURED BREAST IMPLANTS & TISSUE EXPANDERS, IS NOT BASED ON ANY NEW SCIENTIFIC EVIDENCE.  Full Article

Mylan Announces U.S. Launch Of Mesalamine Rectal Suppository, 1000 mg
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Mylan NV ::MYLAN ADDS FIRST GENERIC FOR CANASA® RECTAL SUPPOSITORY TO GROWING GASTROENTEROLOGY PORTFOLIO.MYLAN NV - MESALAMINE RECTAL SUPPOSITORY HAS 180 DAYS OF GENERIC DRUG EXCLUSIVITY.MYLAN NV - ANNOUNCED U.S. LAUNCH OF MESALAMINE RECTAL SUPPOSITORY, 1000 MG, FIRST GENERIC VERSION OF ALLERGAN'S CANASA RECTAL SUPPOSITORY, 1000 MG.  Full Article

Photo

Appaloosa steps up pressure on Allergan to split chairman, CEO roles

BOSTON Hedge fund Appaloosa LP on Tuesday urged pharmaceutical company Allergan Plc to split its chairman and chief executive roles, arguing that an independent chair could help CEO Brent Saunders boost the company's sagging share price.